Author:
Tang Chuanhao,Zhu Lingxiang,Zhang Lijuan,Tan Chianru,Peng Zhiyong,Liu Baoxia,Liu Wenjing,Hu Haixu,Bai Yu,Wang Bo,Lin Li,Liang Jun,Li Xiaoyan,Guo Yong,Liu Yi
Funder
Beijing Municipal Science and Technology Commission
National Natural Science Foundation of China
Research and Development
Subject
Biochemistry, medical,Clinical Biochemistry,Biochemistry,General Medicine
Reference35 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N. Engl. J. Med.,2002
3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
5. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial;Shi;Lancet Oncol.,2013
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献